UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark one)
x		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

			For the quarterly period ended July 1, 2006

	or

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

			For the transition period from to .

			Commission file number: 0-23633

1-800 CONTACTS, INC.

(Exact name of registrant as specified in its charter)

Delaware		87-0571643
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

66 E. Wadsworth Park Drive, Draper, UT		84020
(Address of principal executive offices)		(Zip Code)

(801) 316-5000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

x Yes o No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer o

Accelerated filer x

Non-accelerated filer o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

o Yes x No

As of August 4, 2006, the Registrant had 14,012,169 shares of Common Stock, par value $0.01 per share, outstanding.

1-800 CONTACTS, INC.

INDEX

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements (unaudited)
		Condensed Consolidated Balance Sheets as of December 31, 2005 and July 1, 2006
		Condensed Consolidated Statements of Operations for the Quarter and Two Quarters ended July 2, 2005 and July 1, 2006
		Condensed Consolidated Statements of Cash Flows for the Two Quarters ended July 2, 2005 and July 1, 2006
		Notes to Condensed Consolidated Financial Statements
Item 2.		Management’s Discussion and Analysis of Financial Condition and Results of Operations
Item 3.		Quantitative and Qualitative Disclosures About Market Risk
Item 4.		Controls and Procedures

PART II. OTHER INFORMATION
Item 1.		Legal Proceedings
Item 1A.		Risk Factors
Item 2.		Unregistered Sales of Equity Securities and Use of Proceeds
Item 3.		Defaults Upon Senior Securities
Item 4.		Submission of Matters to a Vote of Security Holders
Item 5.		Other Information
Item 6.		Exhibits

PART 1. FINANCIAL INFORMATION

Item 1. Financial Statements

1-800 CONTACTS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

	December 31,			July 1,
	2005			2006
ASSETS
CURRENT ASSETS:
Cash	$	1,481		$	89
Accounts receivable, net	3,451			3,471
Other receivables	1,738			2,156
Inventories, net	21,458			20,419
Deferred income taxes	1,624			1,817
Other current assets	3,792			2,494
Total current assets	33,544			30,446
PROPERTY AND EQUIPMENT, net	29,705			31,223
DEFERRED INCOME TAXES	1,087			1,006
GOODWILL	35,405			35,963
DEFINITE-LIVED INTANGIBLES, net	13,847			12,639
OTHER ASSETS	1,357			1,726
Total assets	$	114,945		$	113,003

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Line of credit	$	—		$	19,479
Current portion of long-term debt	1,633			2,221
Current portion of capital lease obligations	58			25
Income taxes payable	567			1,747
Accounts payable	12,063			11,487
Accrued liabilities	8,197			11,131
Unearned revenue	3,299			3,219
Total current liabilities	25,817			49,309
LONG-TERM LIABILITIES:
Line of credit	23,746			—
Long-term debt, net of current portion	6,440			5,377
Capital lease obligations, net of current portion	83			59
Unearned revenue, net of current portion	973			—
Other long-term liabilities	669			643
Total long-term liabilities	31,911			6,079
STOCKHOLDERS’ EQUITY
Common stock, 13,340 and 13,360 issued and outstanding, respectively	133			134
Additional paid-in capital	47,876			49,019
Retained earnings	9,613			8,756
Accumulated other comprehensive loss	(405		)	(294		)
Total stockholders’ equity	57,217			57,615
Total liabilities and stockholders’ equity	$	114,945		$	113,003

See accompanying notes to condensed consolidated financial statements.

1-800 CONTACTS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

	Quarter Ended						Two Quarters Ended
	July 2,			July 1,			July 2,			July 1,
	2005			2006			2005			2006
NET SALES	$	61,365		$	63,155		$	121,648		$	126,646
COST OF GOODS SOLD	37,697			40,523			75,472			79,536
Gross profit	23,668			22,632			46,176			47,110
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES:
Advertising	7,120			3,703			13,658			7,686
Legal and professional	906			1,123			2,190			2,248
Research and development	811			1,637			1,866			2,965
Other selling, general and administrative	12,304			15,922			23,821			29,601
Total selling, general and administrative expenses	21,141			22,385			41,535			42,500
INCOME FROM OPERATIONS	2,527			247			4,641			4,610
OTHER INCOME (EXPENSE), net	(1,166		)	352			(1,807		)	665
INCOME BEFORE PROVISION FOR INCOME TAXES	1,361			599			2,834			5,275
PROVISION FOR INCOME TAXES	(1,320		)	(2,637		)	(2,610		)	(6,132		)
NET INCOME (LOSS)	$	41		$	(2,038	)	$	224		$	(857	)

PER SHARE INFORMATION:
Basic and diluted net income (loss) per common share	$	0.00		$	(0.15	)	$	0.02		$	(0.06	)

See accompanying notes to condensed consolidated financial statements.

1-800 CONTACTS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Two Quarters Ended
	July 2,			July 1,
	2005			2006
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	224		$	(857	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	4,291			4,892
Amortization of debt issuance costs and discounts	96			158
Foreign currency exchange loss (gain)	1,060			(1,519		)
Stock-based compensation	44			1,028
Tax benefits from share-based payment exercises	—			(28		)
Loss on sale of property and equipment	107			164
Deferred income taxes	(1,157		)	(112		)
Changes in operating assets and liabilities:
Accounts receivable, net	(749		)	469
Inventories, net	399			1,487
Other receivables	(924		)	(418		)
Other current assets	(651		)	1,340
Income taxes payable	(1,008		)	1,190
Accounts payable	2,412			(1,025		)
Accrued liabilities	2,534			2,863
Unearned revenue	(1,968		)	(1,193		)
Net cash provided by operating activities	4,710			8,439
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(3,473		)	(3,744		)
Proceeds from sale of property and equipment	27			—
Purchase of definite-lived intangible assets	(610		)	—
Deposits and other	(1,610		)	(605		)
Net cash used in investing activities	$	(5,666	)	$	(4,349	)

1-800 CONTACTS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

(in thousands)

(unaudited)

	Two Quarters Ended
	July 2,			July 1,
	2005			2006
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	$	162		$	107
Excess tax benefits from share-based payment exercises	—			28
Net repayments on line of credit	(911		)	(4,267		)
Principal payments on capital lease obligations	(20		)	(62		)
Principal payments on long-term debt	(835		)	(961		)
Net cash used in financing activities	(1,604		)	(5,155		)
EFFECT OF FOREIGN EXCHANGE RATES ON CASH	101			(327		)

NET DECREASE IN CASH	(2,459		)	(1,392		)
CASH AT BEGINNING OF PERIOD	3,105			1,481
CASH AT END OF PERIOD	$	646		$	89

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	509		$	815
Cash paid for income taxes	4,775			5,045

See accompanying notes to condensed consolidated financial statements.

1-800 CONTACTS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1. PRESENTATION OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The accompanying condensed consolidated financial statements have been prepared by 1-800 CONTACTS, INC. (“the Company”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments), which in the opinion of management, are necessary to present fairly the results of operations of the Company for the periods presented. It is suggested that these condensed consolidated financial statements be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005.

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates.

NOTE 2. INVENTORIES

Inventories are recorded at the lower of cost (using the first-in, first-out method) or market value. Elements of cost in the Company’s manufactured inventories generally include raw materials, direct labor, manufacturing overhead and freight-in. Inventories consisted of the following (in thousands):

	December 31,		July 1,
	2005		2006
Purchased contact lenses and accessories	$	13,554	$	10,768
Manufactured inventories:
Raw materials	1,322		1,004
Work in process	1,894		1,422
Finished goods contact lenses	4,688		7,225
Total	$	21,458	$	20,419

Provision is made to reduce excess and obsolete inventories to their estimated net realizable values. As of December 31, 2005 and July 1, 2006, reserves for excess and obsolete inventories were approximately $2.2 million and $2.1 million, respectively.

NOTE 3. NET INCOME (LOSS) PER COMMON SHARE

Basic net income (loss) per common share (“Basic EPS”) excludes dilution and is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other common stock equivalents were exercised or converted into common stock using the treasury stock method. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an antidilutive effect on net income (loss) per common share. Additionally, the Company has not reflected performance based unvested stock awards in Diluted EPS since the performance conditions were not satisfied as of July 1, 2006. For the quarter and two quarters ended July 2, 2005, options to purchase 814,325 and 822,225 shares of common stock, respectively, were not included in the computation of Diluted EPS because the effect would be antidilutive. For the

quarter and two quarters ended July 1, 2006, options to purchase 1,185,090 shares of common stock, as well as 680,878 shares of unvested common stock, were not included in the computation of Diluted EPS because the effect would be antidilutive.

The following is a reconciliation of the numerator and denominator used to calculate Basic and Diluted EPS (in thousands, except per share amounts):

	Quarter Ended July 2, 2005					Quarter Ended July 1, 2006
	Net Income		Shares	Per-Share Amount		Net Loss			Shares	Per-Share Amount

Basic EPS	$	41	13,312	$	0.00	$	(2,038	)	13,360	$	(0.15	)
Effect of stock options			151						—
Effect of unvested stock awards			—						—
Diluted EPS	$	41	13,463	$	0.00	$	(2,038	)	13,360	$	(0.15	)

	Two Quarters Ended July 2, 2005					Two Quarters Ended July 1, 2006
	Net Income		Shares	Per-Share Amount		Net Loss			Shares	Per-Share Amount

Basic EPS	$	224	13,307	$	0.02	$	(857	)	13,352	$	(0.06	)
Effect of stock options			169						—
Effect of unvested stock awards			—						—
Diluted EPS	$	224	13,476	$	0.02	$	(857	)	13,352	$	(0.06	)

NOTE 4. COMPREHENSIVE LOSS

Comprehensive loss for the quarter and two quarters ended July 2, 2005 and July 1, 2006 consisted of the following components (in thousands):

	Quarter Ended						Two Quarters Ended
	July 2, 2005			July 1, 2006			July 2, 2005			July 1, 2006
Net income (loss)	$	41		$	(2,038	)	$	224		$	(857	)
Foreign currency translation gain (loss)	(242		)	112			(360		)	111
Comprehensive loss	$	(201	)	$	(1,926	)	$	(136	)	$	(746	)

The foreign currency translation gain (loss) resulted primarily from changes in exchange rates relative to the U.S. dollar from the translation of the Company’s Singapore and United Kingdom subsidiaries’ financial statements.

NOTE 5. STOCK-BASED COMPENSATION

Effective January 1, 2006, the Company adopted Statement of Financial Accounting Standards (“SFAS”) No. 123 (Revised 2004), “Share-Based Payment,” (“SFAS No. 123R”), which requires stock-based compensation to be measured based on the fair value of the award on the date of grant and recognized over the period during which service is required in exchange for the award. In March 2005, the SEC issued Staff Accounting Bulletin No. 107 (“SAB No. 107”) relating to SFAS No. 123R. The Company has applied the provisions of SAB No. 107 in its adoption of SFAS No. 123R.

Prior to January 1, 2006, the Company applied Accounting Principles Board Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations (“APB 25”), and adopted the disclosure-only provisions of Statement of Financial Accounting Standards No. 123 (“SFAS No. 123”), “Accounting for Stock-Based Compensation.” Under APB 25, no compensation expense was recognized in net income for grants of employee stock options prior to 2006.

SFAS No. 123R applies to all of the Company’s outstanding unvested share-based payment awards as of January 1, 2006 and all prospective awards. All of the Company’s stock-based awards, which are stock options and restricted stock awards, are classified as equity instruments. In accordance with SFAS No. 123R, the Company elected to use the modified prospective transition method and therefore, financial statements prior to adoption remain unchanged. Under this transition method, compensation cost for the quarter and two quarters ended July 1, 2006 includes amounts associated with (i) unvested stock options granted prior to January 1, 2006, (ii) restricted stock awards granted prior to January 1, 2006 and (iii) restricted stock awards granted during the current fiscal year. Compensation cost recognized in fiscal 2006 for unvested options as of January 1, 2006 was based on the grant-date fair value estimated in accordance with the original provisions of SFAS No. 123. The following discusses certain other elections and assumptions the Company made as a result of adopting SFAS No. 123R:

· Black-Scholes Model. For the Company’s pro forma disclosures under SFAS No. 123, it used the Black-Scholes option pricing model. Upon the adoption of SFAS No. 123R, the Company has elected to continue to use the Black-Scholes option pricing model to compute the fair value of options granted on or after January 1, 2006.

· Forfeitures. Forfeitures under SFAS No. 123 were recognized when they occurred. SFAS No. 123R, however, requires forfeitures to be estimated at the grant date. Accordingly, compensation cost is recognized based on the number of awards expected to vest. There may be adjustments in future periods if actual forfeitures differ from the Company’s estimates. The Company’s forfeiture rates are based upon historical experience.

· Short-cut Method. The Company has elected to use the short-cut method in accordance with FSP 123R-3 in measuring its APIC pool available to absorb tax deficiencies recognized in subsequent periods from the exercise of unqualified stock options and vesting of restricted stock awards. Under the short-cut method, the Company has determined that it has no APIC pool as of January 1, 2006. Accordingly, realized tax deficiencies in excess of tax benefits related to fully vested awards as of January 1, 2006 will be recorded as additional income tax expense in the period determined.

Prior to the adoption of SFAS No. 123R, the Company presented tax benefits resulting from share-based compensation as operating cash flows in the consolidated statements of cash flows. SFAS 123R requires that cash flows resulting from tax deductions in excess of compensation cost recognized in the financial statements be classified as financing cash flows. However, under the short-cut method, for all vested awards as of January 1, 2006, any realized tax benefits are recorded as financing cash flows and an increase to additional paid in capital. For the quarter and the two quarters ended July 1, 2006, approximately $1,000 and $28,000 of excess tax benefits, respectively, were generated.

Stock-based expense recorded during fiscal 2006 includes expense, recognized over the applicable vesting periods, for new restricted stock share-based awards and for restricted stock and stock option share-based awards granted prior to, but not yet vested, as of January 1, 2006. As a result of adopting SFAS No. 123R, the stock-based compensation expense for employees and non-employee directors for the quarter and two quarters ended July 1, 2006 totaled approximately $0.7 million and $1.0 million, respectively. The total income tax benefit related to stock-based expense during the quarter and two quarters ended July 1, 2006 were approximately $0.3 million and $0.4 million, respectively. The impact on Basic and Diluted EPS for the quarter and two quarters ended July 1, 2006 was a decrease of approximately $0.03 and $0.04 per share, respectively. In addition, prior to the adoption of SFAS No. 123R, the Company presented the tax benefit from the exercise of common stock option exercises as a component of cash flows from operating activities. Upon the adoption of SFAS No. 123R, tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options are classified as a component of cash flows from financing activities. For the quarter and two quarters ended July 1, 2006, this resulted in a decrease of $1,000 and $28,000, respectively, in cash flows from operating activities and an increase of $1,000 and $28,000, respectively, in cash flows from financing activities compared to cash

flows from stock-based compensation presented under APB 25.

Stock –Based Award Plans

Stock Options. The Company has established a stock incentive plan that provides for the issuance of a maximum 1,940,000 shares of common stock to officers, employees, directors and consultants. The plan allows for the issuance of incentive stock options, nonqualified stock options and restricted stock. Incentive and nonqualified stock options are granted at not less than 100 percent of the fair market value of the underlying common stock on the date of grant. As of July 1, 2006, 45,428 shares were available for future granting.

Prior to the establishment of the stock incentive plan, the Company issued nonqualified stock options to various key employees, a consultant and a director of the Company.

All options granted through January 1, 2000 vest equally over a three-year period and expire in ten years. The stock options issued as a portion of the consideration for the assignment of certain technologies and intellectual property in conjunction with the acquisition of ClearLab International and other options issued to the chief technology officer of ClearLab International vest equally at the end of the third, fourth and fifth years and expire in ten years. All other options granted subsequent to January 1, 2000, vest equally over a four-year period and expire in five to ten years.

Stock options remained outstanding under these various plans as of January 1, 2006. There have been no options granted from these plans during fiscal 2006, and the Company does not currently plan to grant any stock options during the remainder of fiscal 2006. Under SFAS No. 123, pro-forma expense for stock options was calculated using a straight-line vesting schedule over the vesting period of approximately four years. Had the Company used the fair value based accounting method for stock option expense prescribed by SFAS No. 123, the Company’s net income and earnings per share for the quarter and two quarters ended July 1, 2005 would have been reduced to the pro-forma amounts illustrated as follows (in thousands, except per share amounts):

	Quarter Ended			Two Quarters Ended
	July 2, 2005			July 2, 2005
Net income (loss):
As reported	$	41		$	224
Add: Stock-based compensation expense included in reported net income, net of tax	24			27
Deduct: Fair-value based compensation, net of tax	(262		)	(572		)
Pro forma	$	(197	)	$	(321	)

Basic and diluted net income (loss) per common share:
As reported	$	0.00		$	0.02
Pro forma	$	(0.01	)	$	(0.02	)

The Company’s stock option activity during the first two quarters of fiscal 2006 is as follows (in thousands, except option prices and years):

					Weighted
			Weighted		Average
			Average		Remaining	Aggregate
	Number of		Exercise		Contractual	Intrinsic
	Options		Price		Life (Years)	Value

Options outstanding at December 31, 2005	1,243		$	20.90
Exercised	(14	)	7.45
Forfeited	(35	)	23.59
Expired	(9	)	24.26
Options outstanding at July 1, 2006	1,185		$	20.96	3.95	$	1,943

Options vested and expected to vest at July 1, 2006	1,152		20.78		3.96	$	1,943

Options exercisable at July 1, 2006	967		$	19.53	3.97	$	1,943

The total intrinsic value of options exercised during the two quarters ended July 1, 2006 totaled approximately $0.1 million. The total intrinsic value of options exercised during the two quarters ended July 2, 2005 totaled approximately $0.1 million. The weighted average fair value of stock option grants was $11.30 for the first two quarters of fiscal 2005. No stock options were granted in the first two quarters of fiscal 2006.

The fair value of options granted in the two quarters of fiscal 2005 was estimated using the Black-Scholes option valuation model that used the assumptions noted in the table below. Expected volatility and expected dividend yield are based on actual historical experience of the Company’s stock. The expected life represents the period of time that options granted are expected to be outstanding. The risk-free rate is based on the U.S. Treasury security with terms equal to the expected time of exercise as of the grant date.

		Two Quarters Ended
		July 2, 2005
Risk-free interest rate		3.7%
Expected dividend yield		0.0%
Volatility		65.5%
Expected life		5 years

For the quarter and two quarters ended July 1, 2006, stock option expense was recognized on a straight-line basis over the four year vesting period. Approximately $0.3 million and $0.6 million, respectively, was charged to expense in the quarter and two quarters ended July 1, 2006 related to stock options. The Company has applied a weighted average forfeiture assumption of 15.03% in the calculation of such expense.

As of July 1, 2006, there was approximately $1.1 million of unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted-average period of approximately one year.

Cash received from option exercises during the two quarters ended July 1, 2006 was approximately $0.1 million. The total tax benefit generated from options granted prior to December 31, 2005, which were exercised during the two quarters ended July 1, 2006, was approximately $28,000, which was credited to additional paid-in capital.

Restricted Share Awards. During the first fiscal quarter of 2006, the Company’s Board of Directors approved a grant of 599,096 shares of restricted common stock to various employees and executives of the Company. The restricted share grants were valued at the closing stock price on the date of the grant, March 27, 2006, which was $13.14. The restricted share grants include both time-vesting and performance-vesting restricted shares. The time-vesting shares (273,451 awards) vest 20% per year beginning November 30, 2006 and ending November 30, 2010. The performance-vesting shares (325,645 awards) vest upon achievement of certain operational milestones - such as obtaining sources for “doctors only” lenses on competitive terms, development of certain contact lens products and the achievement of an eight quarter cumulative financial target of at least $81 million consolidated earnings before taxes by or before the end of fiscal 2010. Both the time-vesting and the performance-vesting shares are subject to various change in control provisions involving the Company and its subsidiaries that may result in the accelerated vesting of unvested shares as well as conversion of unvested shares into a cash amount at the time of a change in control.

The Company also granted 50,000 shares of restricted common stock to its five non-employee directors. These grants vest equally over a three-year period ending March 27, 2009; the vesting of these awards will be accelerated upon a change in control of the Company. The restricted share grants were also valued at the closing stock price on the date of the grant, March 27, 2006, which was $13.14. An additional 2,500 shares of restricted common stock were granted to one non-employee director. This restricted share grant was valued at the closing stock price on the date of the grant, March 29, 2006, which was $13.28 and vests on July 28, 2006.

The Company’s activity relating to restricted share awards during the first two quarters of fiscal 2006 was as follows (in thousands, except fair values):

	Number of Restricted		Weighted Average Grant Date Fair
	Share Awards		Value Per Award
Unvested at December 31, 2005	36		$	17.82
Granted	652		13.14
Vested	(4	)	22.69
Forfeited and expired	—		—
Unvested at April 1, 2006	684		$	13.51
Vested	(2	)	18.84
Forfeited and expired	(1	)	13.14
Unvested at July 1, 2006	681		$	13.49

For the two quarters ended July 1, 2006, approximately $0.4 million was charged to expense relating to the amortization of the time-vested restricted share awards. At July 1, 2006, unrecognized compensation expense, including estimated forfeitures related to time-vested restricted share awards totaled approximately $4.1 million and will be recognized over a weighted average period of 4.13 years. No restricted share awards vested during the quarter and two quarters ended July 2, 2005. The fair value of restricted share awards that vested during the quarter and two quarters ended July 1, 2006 totaled approximately $26,000 and $82,000, respectively.

Expense related to performance-vesting shares will be recognized once it is determined “probable” that the operational milestones will be met. At the time the achievement of these operational milestones are considered “probable”, the Company will record a cumulative catch-up for the amount of expense that should have been recognized from the date of the grant to the date it was determined achievement was probable and recognize the remaining expense on a straight-line basis through the estimated date of achievement. Currently the Company believes it is not probable that the milestones will be met. Total gross compensation expense, excluding any estimate of forfeitures related to the performance-vesting shares, will be approximately $4.3 million.

NOTE 6. DEBT OBLIGATIONS

December 30, 2005. The modified loan agreement provides for borrowings of up to $30 million, $35 million, or $40 million, depending on the Company’s minimum fixed coverage ratio assessed on a quarterly basis, as defined in the agreement. As of July 1, 2006, the Company could borrow up to $40 million. Subsequent to the second quarter of fiscal 2006, the Company could borrow up to $30 million. Additionally, the agreement provides for letters of credit up to a maximum of $15 million outstanding or payable at any time. The amount of any letters of credit outstanding is deducted from the amount available for borrowing. The maturity date of the loan agreement remains February 27, 2007, as such, the amounts due under the line of credit are reported as current liabilities in the condensed consolidated balance sheet as of July 1, 2006. The Company intends to renew or refinance this line of credit prior to the maturity date. Outstanding borrowings on the revolving credit facility bear interest at a floating rate equal to the lender’s prime interest rate plus a margin or the lender’s LIBOR rate plus a margin. The interest rate is adjusted quarterly and ranges between prime minus 0.25 percent and prime plus 0.25 percent or between the applicable LIBOR rate plus 1.75 percent and the applicable LIBOR rate plus 2.25 percent, depending on the Company’s maximum leverage ratio, as defined in the agreement. As of July 1, 2006, the prime rate margin is 0 percent and the LIBOR rate margin is 2.00 percent. Interest is payable monthly. As of July 1, 2006, the Company’s outstanding borrowings on the credit facility, including bank overdrafts, were $19.5 million. Of this amount, $9.0 million bore interest at the lender’s LIBOR rate plus 2.00 percent (7.32% at July 1, 2006) and the remaining $10.5 million bore interest at the lender’s prime rate plus 0 percent (8.25% at July 1, 2006). The facility requires the quarterly payment of an unused credit fee which ranges from 0.25 percent to 0.38 percent, depending on the Company’s maximum leverage ratio.

Outstanding balances on the credit facility are secured by substantially all of the Company’s U.S. assets, subsidiary debt instruments, 100 percent ownership interests in all domestic subsidiaries and 65 percent ownership interests in foreign subsidiaries directly owned by the Company. The modified loan agreement includes various financial covenants including a capital expenditure limit, a maximum leverage ratio and a minimum fixed charge coverage ratio. The modified loan agreement does not permit the Company or its subsidiaries to dissolve, sell, dispose or merge all of their assets or acquire all of the assets of any entity without the written consent of the U.S. bank, unless the transaction meets the definition of a “Permitted Acquisition Basket”, as defined in the agreement. The modified loan agreement also places a limit on the amount the Company can loan to any entity, outside the normal course of business. Additionally, the modified agreement allows the Company to declare or pay cash dividends, to repurchase its stock or to perform other similar equity transactions if such transactions would not exceed $15 million in any fiscal year and subject to other terms. This agreement defines several customary events of default including any material adverse change or any event that occurs which may cause a material adverse change in the Company’s or its subsidiaries’ condition.

The Company’s Singapore bank term loan contains various financial covenants including minimums on net worth and shareholders’ funds of the Singapore operations. 1-800 CONTACTS, INC. has guaranteed this term loan.

Cross default clauses exist such that if the Company were in default on its U.S. debt, the Company would also be in default on its Singapore debt. If the Company were in default on its Singapore bank term loan, the Company would also be in default on its note payable to the former parent of ClearLab International and its loan agreement with its U.S. bank.

NOTE 7. COMMITMENTS AND CONTINGENCIES

Legal and Regulatory Matters

The sale and delivery of contact lenses are governed by both federal and state laws and regulations, including the federal Fairness to Contact Lens Consumer Act (“FCLCA”). The FCLCA requires that contact lenses only be sold to customers based on the seller obtaining a copy of the prescription itself or verifying the prescription by direct communication with the customer’s prescriber. Consistent with this requirement, the Company’s current operating practice is to require all customers to provide either a valid copy of their prescription or the contact information for their prescriber so that the Company can verify their prescription by direct communication with their prescriber. If the Company does not have a valid copy of the customer’s prescription, the Company directly communicates to the customer’s prescriber the precise prescription information received from the customer and, in accordance with the FCLCA, informs the prescriber that it will proceed with the sale based on this prescription information unless the prescriber advises it within eight business hours that such prescription information is expired

or otherwise invalid. If the prescriber properly advises the Company within this time period that the customer’s prescription is expired or otherwise invalid, the Company’s practice is to cancel the customer’s order. On the other hand, if the prescriber either advises the Company that the prescription is valid or fails to respond properly within the required time period, the Company’s practice is to complete the sale based on the prescription information communicated to the prescriber, as expressly permitted by the FCLCA. The Company retains copies of the written prescriptions that it receives and maintains records of its communications with the customer’s prescriber. The FCLCA provides for several means of direct communication with eye care practitioners, and the Company may alter its prescription verification procedures from time to time in keeping with the FCLCA and FTC guidelines.

From time to time, the Company is involved in legal matters generally incidental to its business. It is the opinion of management, after discussion with legal counsel that, except for legal and professional fees that the Company incurs from time to time, the ultimate dispositions of all of these matters will not have a material impact on the financial position, liquidity or results of operations of the Company. However, there can be no assurance that the Company will be successful in its efforts to satisfactorily resolve these matters, and the ultimate outcome could result in a material negative impact on the Company’s financial position, liquidity or results of operations.

Advertising Commitments

As of July 1, 2006, the Company had entered into certain noncancelable commitments with various advertising companies that will require the Company to pay approximately $3.2 million during the remainder of 2006.

NOTE 8. SEGMENT INFORMATION

The Company has two operating segments. These operating segments represent components of the Company for which separate financial information is available and are evaluated regularly by management in determination of resource allocation and performance assessment. The Company’s U.S. Retail segment includes the operations of 1-800 CONTACTS, a direct marketer of replacement contact lenses. The Company’s International segment includes the operations of ClearLab International and ClearLab UK, developers, marketers, manufacturers and distributors of contact lenses. The U.S. Retail segment includes revenue from the optical retail store agreement and the International segment includes revenue from the Japanese license and royalty agreement. Operating segment information for the quarter and two quarters ended July 2, 2005 and July 1, 2006 is as follows (in thousands):

Quarter Ended July 2, 2005	U.S. Retail		International			Eliminations			Total

Net sales (International segment includes intersegment sales of $3)	$	56,767	$	4,601		$	(3	)	$	61,365
Gross profit	22,857		703			108			23,668
Research and development	—		811			—			811
Other selling, general and administrative expense	10,794		1,510			—			12,304
Income (loss) from operations	$	4,389	$	(1,970	)	$	108		$	2,527

Quarter Ended July 1, 2006	U.S. Retail		International			Eliminations		Total

Net sales	$	57,734	$	5,421		$	—	$	63,155
Gross profit (loss)	22,774		(180		)	38		22,632
Research and development	—		1,637			—		1,637
Other selling, general and administrative expense	12,569		3,353			—		15,922
Income (loss) from operations	$	5,755	$	(5,546	)	$	38	$	247

Two Quarters Ended July 2, 2005	U.S. Retail		International			Eliminations			Total

Net sales (International segment includes intersegment sales of $374)	$	113,133	$	8,889		$	(374	)	$	121,648
Gross profit	45,044		1,306			(174		)	46,176
Research and development	—		1,866			—			1,866
Other selling, general and administrative expense	20,872		2,949			—			23,821
Income (loss) from operations	$	8,792	$	(3,977	)	$	(174	)	$	4,641

Two Quarters Ended July 1, 2006	U.S. Retail		International			Eliminations		Total

Net sales	$	116,907	$	9,739		$	—	$	126,646
Gross profit	46,398		458			254		47,110
Research and development	10		2,955			—		2,965
Other selling, general and administrative expense	24,282		5,319			—		29,601
Income (loss) from operations	$	12,761	$	(8,405	)	$	254	$	4,610

The following reconciles total segment income from operations to income before provision for income taxes for the quarter and two quarters ended July 2, 2005 and July 1, 2006 as follows (in thousands):

	Quarter Ended
	July 2, 2005			July 1, 2006
Income from operations	$	2,527		$	247
Interest expense, net	(347		)	(433		)
Foreign currency exchange transaction gain (loss), net	(748		)	789
Other, net	(71		)	(4		)
Income before provision for income taxes	$	1,361		$	599

	Two Quarters Ended
	July 2, 2005			July 1, 2006
Income from operations	$	4,641		$	4,610
Interest expense, net	(648		)	(846		)
Foreign currency exchange transaction gain (loss), net	(1,060		)	1,519
Other, net	(99		)	(8		)
Income before provision for income taxes	$	2,834		$	5,275

Identifiable segment assets are as follows (in thousands):

Fiscal Year Ended December 31, 2005	U.S. Retail		International		Total

Long-lived assets, net	$	35,130	$	43,827	$	78,957
Total assets	54,758		60,187		114,945

Quarter Ended July 1, 2006	U.S. Retail		International		Total

Long-lived assets, net	$	33,828	$	45,997	$	79,825
Total assets	51,643		61,360		113,003

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

The Company is a direct marketer of replacement contact lenses and is also a manufacturer, developer and distributor of its own branded and private label contact lenses through its operations in Singapore and the United Kingdom. The Company’s U.S. Retail operations sell almost all of the popular brands of contacts lenses, including those manufactured by Johnson & Johnson Vision Care, CIBA Vision, Bausch & Lomb and CooperVision. ClearLab is the Company’s international contact lens development, manufacturing and distribution business. On July 26, 2006 ClearLab introduced its AquaSoft Singles product which is still currently under development. The Company has recently engaged an investment banking firm to evaluate a broad range of strategic alternatives in an effort to capitalize on the value of ClearLab and this new product. Among the options being considered to maximize the value for the Company’s shareholders is the possible separation of ClearLab from the Company.

Japanese License and Royalty Agreement. In December 2004, the Company signed an agreement which grants Menicon Co., LTD (Menicon), Japan’s largest independent contact lens manufacturer, exclusive rights to develop, manufacture and market certain disposable contact lenses and related intellectual property in Japan. Under the terms of the agreement, Menicon licenses from the Company different types of intellectual property, including contact lens material, manufacturing technology and related knowledge. As of the second quarter of fiscal 2006, the Company has received a total of $10 million under the agreement; the Company will receive an additional $3 million of guaranteed payments under this agreement through December 31, 2007.

Optical Retail Store Agreement. During the latter part of 2004, the Company entered into an agreement with a regional optical retail chain in Utah. Under the terms of the agreement, the companies effectively combined their contact lens business in Utah and began jointly serving these customers in December 2004. The objective of this agreement is to partner with an optical retailer to create a seamless experience for consumers that will include exams as well as in-store, phone and online service.

Under the agreement, the Company fulfills substantially all orders taken at the retail optical chain for contact lenses and both parties share in the operating results of the combined contact lens business based on a certain allocation percentage. However, during the term of the agreement, the Company guaranteed that the retail chain would receive at least $0.5 million of annual earnings under the arrangement. Additionally, the Company committed to purchase approximately $0.3 million per year in inventory from the retail chain’s source of supply. Under the arrangement, the Company records gross revenues for all orders fulfilled and records selling, general and administrative expense for the retail chain’s share of the net operating results.

This agreement expired in January 2006; however, both parties continue to operate their contact lens businesses jointly as they work towards confirming the terms of a new arrangement. The Company is deferring any decision to launch a national network with optical retail stores until a resolution can be found to industry practices relating to “doctors only” lenses and after a review of the Company’s progress with the doctor referral network.

Doctor Referral Network. The Company is currently expanding its national doctor referral network with select optical retail chains and independent practitioners and plans to have approximately 1,000 locations for referrals in its network by the end of the third quarter of fiscal 2006. Under this referral program, when a current or potential customer needs a new contact lens prescription, the Company can facilitate the process of obtaining an eye examination through this network of providers. This process minimizes the interruptions in product consumption for the consumer and improves the Company’s ability to capture new customers and retain its current customers.

The Company is developing this referral program under the brand name ProNet. ProNet will serve as the division of the Company dedicated to the national doctor referral network. The Company launched a website in support of the ProNet brand during March 2006. This website serves as a tool to assist ProNet in recruiting providers and communicating with the optical community.

Supplier Agreements. The Company has agreements with its top two vendors for improved pricing and marketing support. This support comes in the form of cooperative marketing and rebate programs designed to promote the manufacturer’s products and build sales. As part of its ongoing relationship with its suppliers, the

Company periodically reviews its specific marketing plans and negotiates cooperative marketing programs and product pricing.

Regulatory Considerations

Fairness to Contact Lens Consumer Act. In November 2003, Congress passed the Fairness to Contact Lens Consumer Act (“FCLCA”), which establishes a national uniform standard for both eye care practitioners and direct marketers with regard to releasing and verifying consumer contact lens prescriptions as well as other requirements relating to the sale of contact lenses. The FCLCA became effective February 4, 2004, and now requires all eye care practitioners to give patients a copy of their prescription as soon as they have been fitted for contact lenses, whether the patients ask for it or not. It also directs contact lens sellers to contact eye care practitioners to request verification of consumer prescriptions before shipping all orders (if the prescription is not already on file), and it provides that failure to respond within eight business hours shall result in the prescription being presumed valid, thereby eliminating the ability of eye care practitioners to impede sales by direct marketers simply by ignoring or refusing to respond to their requests to verify prescriptions. The FCLCA also provides that prescriptions will be valid for a minimum of at least one year (absent some special medical reason justifying a shorter period). It also directed the Federal Trade Commission (“FTC”) to conduct a study examining the strength of competition in the market for contact lenses and to submit a report to Congress within twelve months of the FCLCA effective date. This FTC completed and published this study on February 15, 2005, with no recommendations for further changes in federal law.

Satisfying the prescription verification requirement of the FCLCA obligates a contact lens seller either to obtain a copy of the prescription itself or to verify the prescription by direct communication with the customer’s prescriber. Consistent with this requirement, the Company’s current operating practice is to require all customers to provide either a valid copy of their prescription or the contact information for their prescriber so that the Company can verify their prescription by direct communication with their prescriber. If the Company does not have a valid copy of the customer’s prescription, the Company directly communicates to the customer’s prescriber the precise prescription information received from the customer and informs the prescriber that it will proceed with the sale based on this prescription information unless the prescriber advises it within eight business hours that such prescription information is expired or otherwise invalid. If the prescriber properly advises the Company within this time period that the customer’s prescription is expired or otherwise invalid, the Company’s practice is to cancel the customer’s order. On the other hand, if the prescriber either advises the Company that the prescription is valid or fails to respond properly within the required time period, the Company’s practice is to complete the sale based on the prescription information communicated to the prescriber, as expressly permitted by the FCLCA. The Company retains copies of the written prescriptions that it receives and maintains records of its communications with the customer’s prescriber. The FCLCA provides for several means of direct communication with eye care practitioners, and the Company may alter its prescription verification procedures from time to time in keeping with the FCLCA and FTC guidelines.

Results of Operations

The Company’s fiscal year consists of a 52/53-week period ending on the Saturday nearest to December 31. The Company’s 2006 fiscal year is a 52-week year and will end on December 30, 2006.

The Company has two operating segments referred to below. The Company’s domestic segment is represented by operations within the U.S. and is referred to as “U.S. Retail” by the Company, whereas the Company’s international segment is represented by operations in both Singapore and the U.K. and is referred to as “ClearLab” by the Company.

The following table presents the Company’s results of operations expressed as a percentage of net sales for the periods indicated:

	Quarter Ended				Two Quarters Ended
	July 2,		July 1,		July 2,		July 1,
	2005		2006		2005		2006
NET SALES	100.0	%	100.0	%	100.0	%	100.0	%
COST OF GOODS SOLD	61.4		64.2		62.0		62.8
Gross profit	38.6		35.8		38.0		37.2

SELLING, GENERAL & ADMINISTRATIVE EXPENSES:
Advertising	11.6		5.9		11.2		6.1
Legal and professional	1.5		1.8		1.8		1.8
Research and development	1.3		2.6		1.5		2.3
Other selling, general & administrative	20.1		25.1		19.7		23.4
Total selling, general & administrative expenses	34.5		35.4		34.2		33.6
INCOME FROM OPERATIONS	4.1		0.4		3.8		3.6
OTHER INCOME (EXPENSE), net	(1.9	)	0.6		(1.5	)	0.5
INCOME BEFORE PROVISION FOR INCOME TAXES	2.2		1.0		2.3		4.1
PROVISION FOR INCOME TAXES	(2.1	)	(4.2	)	(2.1	)	(4.8	)
NET INCOME (LOSS)	0.1	%	(3.2	)%	0.2	%	(0.7	)%

Net sales. Net sales for the quarter ended July 1, 2006 increased 2.9% to $63.2 million from $61.4 million for the quarter ended July 2, 2005. For the two quarters ended July 1, 2006, net sales increased 4.1% to $126.6 million from $121.6 million for the two quarters ended July 2, 2005. Net sales for the Company’s U.S. Retail operations, for the second quarter of fiscal 2006 and the first two quarters of fiscal 2006, were $57.7 million and $116.9 million, respectively, an increase from the prior year periods of 1.7% and 3.3%, respectively. U.S. Retail net sales increased primarily from an increase in sales on the Internet due mainly to upgrades the Company made to its website during fiscal 2005 and from targeted online marketing programs.

During the quarter and two quarters ended July 1, 2006 the Company spent approximately $3.7 million and $7.7 million, respectively, on advertising. During the quarter and two quarters ended July 2, 2005 the Company spent approximately $7.1 million and $13.7 million, respectively, on advertising . The Company’s reduction in advertising spending during the first two quarters from the first two quarters of fiscal 2005 is consistent with the Company’s strategy to spend less on advertising in fiscal 2006 as the Company focuses on addressing the threat of ‘doctors only’ lenses. The Company expects that U.S. Retail net sales will continue to be impacted by the decrease in advertising spending during fiscal 2006. Additionally, U.S. Retail net sales growth continues to be constrained by lost sales related to certain ‘doctors only’ contact lenses that the Company cannot obtain in order to fill orders for customers who wish to purchase the product.

Net sales for ClearLab for the second quarter of fiscal 2006 and the first two quarters of fiscal 2006 were $5.4 million and $9.7 million, respectively. Net sales for ClearLab for the second quarter of fiscal 2005 and the first two quarters of fiscal 2005 were $4.6 million and $8.9 million, respectively. ClearLab’s results for the second quarter and first two quarters of fiscal 2006 included $1.5 million and $3.0 million, respectively, in license fees from the Company’s Japanese license agreement, compared to $1.0 million and $2.0 million in the second quarter and first two quarters of fiscal 2005, respectively. The increase in license fees for the first two quarters of fiscal 2006 was offset by a decrease of $0.4 million in intercompany sales to the Company’s U.S. Retail business, as ClearLab recorded no sales to the U.S. Retail business in the first two quarters of fiscal 2006. ClearLab’s sales have been negatively impacted by sales delays to external customers due to product and packaging improvements, including the recent introduction of ClearLab’s new lens design and manufacturing process improvements.

Gross profit. Consolidated gross profit as a percentage of net sales decreased to 35.8% for the quarter ended July 1, 2006 from 38.6% for the quarter ended July 2, 2005. For the two quarters ended July 1, 2006, consolidated gross profit as a percentage of net sales decreased to 37.2% from 38.0% for the two quarters ended July 2, 2005.

Gross profit as a percentage of net sales for the Company’s U.S. Retail operations decreased to 39.4% in the second quarter of fiscal 2006 from 40.3% in the second quarter of fiscal 2005. Gross profit as a percentage of net sales for the Company’s U.S. Retail operations decreased slightly to 39.7% from 39.8% for the two quarters ended July 1, 2006 and July 2, 2005, respectively. This decrease from last year was due largely to increases in select product costs and shipping rates. The Company expects the U.S. Retail gross profit margin for the balance of fiscal 2006 to approximate the margin achieved for the second quarter of fiscal 2006.

Gross profit (loss) as a percentage of net sales for ClearLab was (3.3)% and 4.7% for the second quarter and two quarters ended July 1, 2006, respectively. Gross profit as a percentage of net sales for ClearLab was 15.3% and 14.7% for the second quarter and two quarters ended July 2, 2005. The second quarter margin for fiscal 2006 was impacted by provisions of approximately $1.2 million recorded on certain inventory. The majority of this inventory was produced prior to the introduction of a new daily lens design. The Company expects to see improvement in gross margins from ClearLab during the remainder of fiscal 2006.

Advertising expense. Advertising expense for the quarter ended July 1, 2006 decreased to $3.7 million from $7.1 million for the quarter ended July 2, 2005. As a percentage of net sales, advertising expense for the second quarter of fiscal 2006 decreased to 5.9% from 11.6% for the second quarter of fiscal 2005. For the two quarters ended July 1, 2006, advertising expense decreased to 6.1% from 11.2% for the first two quarters of fiscal 2005. The Company expects to decrease fiscal 2006 advertising expenses by approximately $10 to $12 million from fiscal 2005 as it continues to focus its resources towards legislative and public relations initiatives. If, however, opportunities present themselves, the Company may increase advertising spending above currently planned levels. The Company’s experience has been that increases in advertising expenditures have a direct impact on the growth of net sales not only in the current period but also in future periods.

The Company expenses all advertising costs when the advertising first takes place. As a result, quarter-to-quarter comparisons are impacted within and between quarters by the timing of television, radio and Internet advertisements and by the mailing of the Company’s printed advertisements. The volume of mailings and other advertising may vary in different quarters and from year to year depending on the Company’s assessment of prevailing market opportunities.

Legal and professional fees. Legal and professional fees for the quarter ended July 1, 2006 increased $0.2 million, or 24%, from the second quarter ended July 2, 2005. As a percentage of net sales, legal and professional fees increased to 1.8% for the second quarter of fiscal 2006 from 1.5% for the second quarter of fiscal 2005. For the two quarters ended July 1, 2006, legal and professional fees increased by $0.1 million to $2.2 million from the two quarters ended July 2, 2005. As a percentage of net sales, legal and professional fees remained constant at 1.8% for the first two quarters of fiscal 2006 compared to the first two quarters of fiscal 2005.

During the first two quarters of fiscal 2006, the Company continued to incur professional fees for Sarbanes-Oxley compliance, and other internal control initiatives, as well as ongoing legal, lobbying and

regulatory initiatives. The Company will continue to focus its efforts on compliance with federal rules and regulations as well as continue to support legal and legislative initiatives that it believes will benefit contact lens wearers. As such, the Company expects to experience continued increases in legal and professional fees during the balance of fiscal 2006 to support these legislative initiatives.

Research and development expenses. Research and development expenses for the quarter ended July 1, 2006 increased to $1.6 million, or 2.6% of net sales, from $0.8 million, or 1.3% of net sales, from the quarter ended July 2, 2005. For the two quarters ended July 1, 2006, research and development expenses were $3.0 million, or 2.3% of net sales, up from $1.9 million, or 1.5% of net sales, for the two quarters ended July 2, 2005. During the first two quarters of fiscal 2006, the Company continued to fund research and development efforts for ClearLab’s operations.

Total fiscal 2006 research and development costs will be dependent on progress with research and development efforts relating to expanding ClearLab’s product offering and developing its intellectual property, including it’s recently introduced AquaSoft Singles product.

Other selling, general and administrative expenses. Other selling, general and administrative expenses for the quarter ended July 1, 2006 increased approximately $3.6 million, or 29.4%, to $15.9 million from the quarter ended July 2, 2005. As a percentage of net sales, other selling, general and administrative expenses for the second quarter of fiscal 2006 also increased to 25.1%, from 20.1% for the second quarter of fiscal 2005. As a percentage of net sales, other selling, general and administrative expenses for the two quarters ended July 1, 2006 increased to 23.4% from 19.7% for the two quarters ended July 2, 2005, as such expenses increased by approximately $5.8 million for the same period. The results for the second quarter of fiscal 2006 include approximately $0.3 million of expense related to stock options granted prior to fiscal 2006 and approximately $0.4 million of expense related to the restricted stock grants, compared to approximately $39,000 of expense related to restricted stock grants in the second quarter of fiscal 2005. Likewise, the results for the first two quarters of fiscal 2006 include approximately $0.6 million of expense related to stock options granted prior to fiscal 2006 and approximately $0.4 million of expense related to restricted stock grants, compared to approximately $44,000 of expense related to restricted stock grants in the first two quarters of fiscal 2005.

The Company’s U.S. Retail other selling, general and administrative expenses increased approximately $1.8 million for the quarter ended July 1, 2006 from the quarter ended July 2, 2005. For the two quarters ended July 1, 2006, U.S. Retail other selling, general and administrative expenses increased $3.4 million from the two quarters ended July 2, 2005. Additionally, such expenses also increased as a percentage of net sales to 21.8% and 20.8%, respectively, for the quarter and two quarters ended July 1, 2006, compared to 19.0% and 18.4% for the quarter and two quarters ended July 2, 2005, respectively. The majority of the increase for U.S. Retail from the quarter and two quarters ended July 2, 2005 related to planned increases in employee costs. These increases include restricted stock and stock option expense, as discussed above, as well as employee costs to support current operations such as costs to strengthen and build the Company’s information technology organization and costs to support a retail network, an initiative which is currently focused on expanding our doctor referral network. Additionally, increases in other selling, general and administrative expenses related to supporting the Company’s legislative efforts.

ClearLab’s other selling, general and administrative expenses increased by approximately $1.8 million for the quarter ended July 1, 2006 from the quarter ended July 2, 2005. ClearLab’s other selling, general and administrative expenses increased by approximately $2.4 million for the two quarters ended July 1, 2006 from the two quarters ended July 2, 2005. A majority of ClearLab’s increase in both the quarter and two quarters ended July 1, 2006 related to costs to strengthen its management team and costs related to the introduction of the AquaSoft Singles product.

Other income (expense), net. Other income (expense) increased to approximately $0.4 million and $0.7 million for the quarter and two quarters ended July 1, 2006, respectively, from approximately $(1.2) million and $(1.8) million for the quarter and two quarters ended July 2, 2005, respectively. For the second quarter of fiscal 2006, other income consisted of approximately $0.8 million in foreign currency exchange transaction gains offset by approximately $0.4 million in interest expense. Other expense in the second quarter of fiscal 2005 consisted mainly of approximately $0.7 million in foreign currency exchange transaction losses and approximately $0.3 million in interest expense. For the two quarters ended July 1, 2006 other income consisted mainly of approximately $0.8 million in interest expense and $1.5 million of foreign currency exchange transaction gains. For the two quarters

ended July 2, 2005, other expense consisted mainly of interest expense of approximately $0.6 million and foreign currency exchange transaction losses of approximately $1.1 million. Interest expense is incurred primarily due to the use of the Company’s credit facility and other debt. The exchange gains and losses relate primarily to intercompany loans to ClearLab.

Income taxes. The Company is taxed in three separate jurisdictions - the U.S., Singapore and the United Kingdom. The Company’s effective U.S. income tax rate for the two quarters ended July 1, 2006 was approximately 44%, as compared with the U.S. income tax rate for the two quarters ended July 2, 2005 of 39%. The increase in the effective U.S. income tax rate primarily resulted from the increase in permanent nondeductible expenses, including those relating to the Company’s lobbying efforts.

During the second quarter of fiscal 2006 the Company elected not to finalize the pioneer tax certificate in order to renegotiate the potential benefits and time period for a pioneer tax certificate in Singapore. Through the first quarter of fiscal 2006, the Company’s Singapore operations had met the requirements for the pioneer tax certificate in Singapore. This pioneer tax certificate allowed for a seven-year tax holiday that reduced the Singapore statutory tax rate to 0% on qualified income for 2003 and future periods through the end of the tax holiday. Without the tax holiday, the Singapore statutory tax rate is 20%. During the first two quarters of fiscal 2006, the Company did not record a tax benefit for the loss from the operations of ClearLab International due to the uncertainty with respect to the realization of a tax benefit in Singapore relating to losses. In the first quarter of fiscal 2006 the Company recorded a current tax provision in Singapore due to Japanese withholding tax on payments received from the Japanese license agreement. The foreign tax credit for this Japanese withholding tax is not eligible for carryforward in the Singapore tax jurisdiction.

For the first two quarters of fiscal 2006, the Company recorded a valuation allowance for the full amount of deferred income tax assets in excess of taxable temporary differences in Singapore and the U.K., as it is more likely than not that these deferred tax assets will not be realized.

The Company expects that its fiscal 2006 effective income tax rates will approximate 44% for the U.S. operations. For the U.K. and Singapore operations, the Company expects that the effective tax rate will be 0%, with the exception of the Japanese withholding tax on license payments made to ClearLab International. The Company’s effective income tax rates may change as facts and circumstances change.

Liquidity and Capital Resources

The Company’s principal sources of liquidity have been cash provided by operating activities and proceeds from debt financings. The Company’s principal uses of cash have been to meet debt service requirements, finance acquisitions, finance capital expenditures, fund working capital needs and repurchase common stock. The Company anticipates that these uses will continue to be the principal demands on its cash in the future. As of July 1, 2006, the Company had net working capital (deficit) of approximately $(18.9) million, compared to $7.7 million as of December 31, 2005. This large decrease in net working capital in the second quarter of fiscal 2006 relates to the Company’s line of credit that is now classified as current on the condensed consolidated balance sheet as the maturity date is February 27, 2007. The Company intends to renew or refinance this line of credit prior to the maturity date.

The Company believes that its cash on hand, together with cash generated from operating activities and the borrowings available through its credit facility, will be sufficient to support planned operations through the foreseeable future. The Company announced on July 26, 2006 that it had engaged an investment bank to assist in performing a strategic review of ClearLab. Based on its strategic review of ClearLab, the Company may determine to retain a portion or all of ClearLab and may continue developing its operations and products. In order to fully commercialize its products, particularly the AquaSoft Singles product, the Company anticipates that ClearLab will require significant additional funding over the foreseeable future, which may not be available through the Company’s cash flows from operations, and will likely require the Company to secure alternative funding. Should the Company’s plans or expectations change, related to ClearLab or otherwise, the Company may be required to seek additional sources of funds and there can be no assurance that such funds will be available on satisfactory terms. Failure to obtain such financing could delay or prevent the Company’s planned growth, and could adversely affect the Company’s business, financial condition, liquidity and results of operations.

As a result of regulatory requirements, the Company’s liquidity, capital resources and results of operations may be negatively impacted in the future if the Company incurs increased costs (including legal fees) or fines, is prohibited from selling its products or experiences losses of a substantial portion of the Company’s customers for whom the Company is unable to obtain or verify a prescription due to the requirements of the FCLCA.

The Company has a loan agreement with a U.S. bank providing for a revolving credit facility. On January 13, 2006, the Company entered into a modified agreement which modified this loan agreement effective as of December 30, 2005. The modified loan agreement provides for borrowings of up to $30 million, $35 million or $40 million, depending on the Company’s minimum fixed coverage ratio assessed on a quarterly basis, as defined in the agreement. As of July 1, 2006, the Company could borrow up to $40 million. Subsequent to the second quarter of fiscal 2006, the Company could borrow up to $30 million. Additionally, the agreement provides for letters of credit up to a maximum of $15 million outstanding or payable at any time. The amount of any letters of credit outstanding is deducted from the amount available for borrowing. The maturity date of the loan agreement remains February 27, 2007, as such, the amounts due under the line of credit are reported as current liabilities in the condensed consolidated balance sheet as of July 1, 2006. The Company intends to renew or refinance this line of credit prior to the maturity date. However, there can be no assurance that the Company will be able to renew or refinance the line of credit on satisfactory terms; which could adversely affect the Company’s business, financial condition, liquidity and results of operations. Outstanding borrowings on the revolving credit facility bear interest at a floating rate equal to the lender’s prime interest rate plus a margin or the lender’s LIBOR rate plus a margin. The interest rate is adjusted quarterly and ranges between prime minus 0.25 percent and prime plus 0.25 percent or between the applicable LIBOR rate plus 1.75 percent and the applicable LIBOR rate plus 2.25 percent, depending on the Company’s maximum leverage ratio, as defined in the agreement. As of July 1, 2006, the prime rate margin is 0 percent and the LIBOR rate margin is 2.00 percent. Interest is payable monthly. As of July 1, 2006, the Company’s outstanding borrowings on the credit facility, including bank overdrafts, were $19.5 million. Of this amount, $9.0 million bore interest at the lender’s LIBOR rate plus 2.00 percent (7.32% at July 1, 2006) and the remaining $10.5 million bore interest at the lender’s prime rate plus 0 percent (8.25% at July 1, 2006). The facility requires the quarterly payment of an unused credit fee which ranges from 0.25 percent to 0.38 percent, depending on the Company’s maximum leverage ratio.

financial covenants including a capital expenditure limit, a maximum leverage ratio and a minimum fixed charge coverage ratio. The modified loan agreement does not permit the Company or its subsidiaries to dissolve, sell, dispose or merge all of their assets or acquire all of the assets of any entity without the written consent of the U.S. bank, unless the transaction meets the definition of a “Permitted Acquisition Basket”, as defined in the agreement. The modified loan agreement also places a limit on the amount the Company can loan to any entity, outside the normal course of business. Additionally, the modified agreement allows the Company to declare or pay cash dividends, to repurchase its stock or to perform other similar equity transactions if such transactions would not exceed $15 million in any fiscal year and subject to other terms. This agreement defines several customary events of default including any material adverse change or any event that occurs which may cause a material adverse change in the Company’s or its subsidiaries’ condition.

As of July 1, 2006, the Company had an unsecured, non-interest bearing note to ClearLab International’s chief technology officer with a principal balance of SGD$813,000 (USD$509,000). The note payable is discounted at 7%. Payments are due in equal monthly installments through July 2007.

As of July 1, 2006, the Company had a term loan payable to a Singapore bank with a principal balance of SGD$4,610,000 (USD$2,886,000) that bears interest at 6.75% and is secured by substantially all of the assets of ClearLab International. Interest payments are due monthly. Principal payments are due in monthly installments through December 2007. This note also contains various financial covenants including minimums on net worth and shareholders’ funds. 1-800 CONTACTS, INC. has guaranteed this term loan.

As of July 1, 2006, the Company also had a note payable to the former parent of ClearLab International with a principal balance of SGD$6,892,000 (USD$4,315,000) that bears interest at 6% and has a subordinated position to the term loan payable to the Singapore bank. The note payable is discounted at 7%. Interest payments are due monthly. Principal payments are due in monthly installments from January 2008 through December 2009. 1-800 CONTACTS, INC. has guaranteed this note.

Cash flows from operating activities. For the two quarters ended July 1, 2006 and July 2, 2005, net cash provided by operating activities was approximately $8.4 million and $4.7 million, respectively. During the fiscal 2006 period, cash provided by operating activities was primarily from net income adjusted for non-cash items such as depreciation, amortization and stock compensation, increases in the income tax payable and accrued liabilities as well as decreases in other current assets and inventories. The increase in cash was partially offset by decreases in accounts payable and unearned revenue as well as the adjustment to net income for the foreign currency exchange gain. In the fiscal 2005 period, cash was provided primarily by net income adjusted for non-cash items and increases in accounts payable and accrued liabilities as well as by decreases in inventories. The increase in cash was partially offset by increases in accounts receivable, other receivables and other current assets as well as from decreases in income taxes payables and unearned revenue.

Cash flows from investing activities. The Company used approximately $4.3 million and $5.7 million for investing activities in the two quarters ended July 1, 2006 and July 2, 2005, respectively. During the first two quarters of fiscal 2006 , the Company paid approximately $0.5 million towards software licenses. In the first two quarters of fiscal 2005, the Company paid approximately $1.5 million in deposits on manufacturing equipment at ClearLab. The Company also purchased approximately $0.6 million of intangible assets during the fiscal 2005 period.

Capital expenditures for infrastructure improvements for the two quarters ended July 1, 2006 and July 2, 2005 were approximately $3.7 million and $3.5 million, respectively. Of these amounts, approximately $2.7 million and $2.6 million relate to purchases made at ClearLab, during the respective periods. The Company anticipates additional capital expenditures in fiscal 2006 for infrastructure as it continues to expand and improve operating

facilities, telecommunications systems and management information systems in order to handle future operations of both its U.S. and international operations.

Financing activities. During the two quarters ended July 1, 2006 and July 2, 2005, net cash used in financing activities was approximately $5.2 million and $1.6 million, respectively. In the first two quarters of 2006, the Company had net repayments on its credit facility of approximately $4.3 million and made principal payments on debt obligations and capital lease obligations of approximately $1.0 million. In the first two fiscal quarters of 2005, the Company paid down its credit facility by approximately $0.9 million and made principal payments on debt obligations and capital lease obligations of approximately $0.9 million. In the first two fiscal quarters of both 2006 and 2005, these amounts were partially offset by proceeds from the exercise of common stock options.

The Company leases various manufacturing and other equipment from financing companies under capital lease arrangements. All of the equipment is maintained at the Company’s Singapore and United Kingdom facilities. The majority of the leases were assumed in connection with the Company’s acquisitions of ClearLab International and ClearLab UK. As of July 1, 2006, the present value of future minimum lease payments was approximately $0.1 million with payments scheduled through fiscal 2009.

Contractual Obligations and Commitments

Subsequent to December 31, 2005, there have been no material changes to the Company’s contractual obligations and commitments, outside the normal course of business.

New Accounting Pronouncements

In June 2006, the Financial Accounting Standards Board (FASB) issued Interpretation No. 48, “Accounting for Uncertainty in Income Taxes,” which defines the threshold for recognizing the benefits of tax return positions in the financial statements as “more-likely-than-not” to be sustained by the taxing authority. A tax position that meets the “more-likely-than-not” criterion shall be measured at the largest amount of benefit that is more than 50% likely of being realized upon ultimate settlement. Interpretation No. 48 applies to all tax positions accounted for under SFAS No. 109, “Accounting for Income Taxes.” Interpretation No. 48 is effective for fiscal years beginning after December 15, 2006. Upon adoption, the Company will adjust its financial statements to reflect only those tax positions that are more-likely-than-not to be sustained as of the adoption date. Any adjustment will be recorded directly to the beginning retained earnings balance in the period of adoption and reported as a change in accounting principle. The Company is currently analyzing the effects of adopting Interpretation No. 48.

Critical Accounting Policies

Accounting polices that require significant judgments and estimates include revenue recognition (including sales returns and allowances and customer rebates); realizability of inventories; realizability of deferred income tax assets; assessment of realizability of long-lived assets; stock-based compensation; and legal and regulatory contingencies. A description of the Company’s significant accounting policies is included in the notes to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2005. Judgments and estimates are based on historical experience as well as relevant facts and circumstances known at each reporting date. Actual results may differ from these estimates.

Sales are generally recognized when products are shipped and the customer takes ownership and assumes risk of loss, collection of the related receivable is reasonably assured, persuasive evidence of an arrangement exists and the sales price is fixed or determinable. U.S. Retail net sales consist of product sales less a provision for sales returns and allowances and estimated customer rebates. The Company accrues an estimated amount for unclaimed customer rebates and sales returns and allowances based on historical information, adjusted for economic trends. To the extent actual rebates, returns and allowances vary from historical experience revisions to the allowances may be required. ClearLab net sales consist of product sales less a provision for sales returns and allowances. The Company provides its customers with standard industry payment terms and performs ongoing credit evaluations of its customers and provides for doubtful accounts to the extent determined necessary based on historical data and current economic trends. ClearLab net sales also include license fees from the Company’s Japanese license agreement. Cash payments received from this license are recognized systematically over the periods that the fees are earned by the Company.

In assessing the realizability of inventories, the Company makes judgments as to future demand requirements and product expiration dates. The inventory requirements change based on projected customer demand, which changes due to fluctuations in market conditions and product life cycles.

The Company has significant long-lived tangible and intangible assets consisting primarily of property, plant and equipment, goodwill and definite-lived intangibles. These assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of such assets may not be recoverable. In addition, the Company performs an impairment test related to goodwill at least annually. An impairment analysis related to long-lived tangible and definite-lived intangible assets requires the assessment of expected future undiscounted cash flows over the remaining useful life of the asset. An impairment analysis of goodwill requires the use of a fair-value

based analysis. All of the goodwill and a significant portion of the other long-lived assets were generated from the Company’s acquisitions of ClearLab International, ClearLab UK and Lens1st/Lens Express. During the second quarter of fiscal 2006, the Company prepared an impairment analysis and determined there was no impairment on any of the Company’s long-lived assets, definite-lived intangible assets or goodwill as of July 1, 2006. If forecasts and assumptions used to support the realizability of long-lived assets change in the future, significant impairment charges could result that would adversely affect the Company’s results of operations and financial position.

Deferred income tax assets are assessed for recoverability and valuation allowances are provided as necessary to reduce deferred income tax assets to amounts expected to be realized. Should expectations of taxable income change in future periods, it may become necessary to change the valuation allowance, which could affect the Company’s results of operations in the period such determination is made. The Company records an income tax provision or benefit at a rate that is based on expected results for the fiscal year. If future changes in market conditions cause actual results to be more or less favorable, adjustments to the effective income tax rate on a quarterly basis could be required.

The Company records liabilities for legal and regulatory matters when the contingency is both probable and reasonably estimable. The Company is involved in several legal and regulatory matters. The Company, after consultation with legal counsel, believes that the ultimate dispositions of these matters will not have a material negative impact on its financial position, liquidity or results of operations. However, there can be no assurance that the Company will be successful in its efforts to satisfactorily resolve these matters and the ultimate outcome could result in a material negative impact on the Company’s financial position, liquidity or results of operations.

Effective January 1, 2006, the Company adopted the fair value recognition provisions of SFAS No. 123R, using the modified prospective transition method, and therefore has not restated prior periods’ results. Under this method the Company recognizes compensation expense for all share-based payments granted after January 1, 2006 and prior to but not yet vested as of January 1, 2006, in accordance with SFAS No. 123R. Under the fair value recognition provisions of SFAS No. 123R, the Company recognizes stock-based compensation net of an estimated forfeiture rate and only recognizes compensation cost for those shares expected to vest over the requisite service period of the award. Prior to SFAS No. 123R adoption, the Company accounted for share-based payments under APB No. 25. Therefore, the Company generally recognized compensation expense for restricted stock awards and when it granted options with an exercise price below the market price on the date of grant. The Company estimates the value of stock option awards on the date of grant using a Black-Scholes pricing model. Calculating the fair value of share-based payment awards requires the input of highly subjective assumptions, including the expected term of the share-based payment awards and expected stock price volatility. The expected term represents the average time that options that vest are expected to be outstanding. The expected volatility rates are estimated based on a weighted average of the historical volatilities of the Company’s common stock. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, its stock-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. If the Company’s actual forfeiture rate is materially different from its estimate, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.

Forward-Looking Statements

Except for historical information contained herein, the matters discussed in this Form 10-Q are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 7A of the Securities Act of 1933, as amended. Words such as “believes,” “anticipates,” “expects,” “future,” “intends,” “would,” “may” and similar expressions are intended to identify forward-looking statements. The Company undertakes no obligation to revise any of these forward-looking statements to reflect events or circumstances after the date hereof. These forward-looking statements involve risks and uncertainties and often depend on assumptions, data or methods that may be incorrect or imprecise. The Company’s future operating results may differ materially from the results discussed in, or implied by, forward-looking statements made by the Company. Factors that may cause such differences include, but are not limited to, general economic conditions, the health and size of the contact lens industry, consumer acceptance of ClearLab’s products, product health benefits, successful completion and implementation of the recommendations from the strategic review of ClearLab, inventory acquisition and

management, manufacturing operations, legislative efforts and results, governmental regulations and other regulatory considerations, exchange rate fluctuations, advertising spending and effectiveness, unanticipated costs and expected benefits associated with license agreements and supply agreements, research and development initiatives, and prescription requirements of The Fairness to Contact Lens Consumers Act.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. As of July 1, 2006, the Company was exposed to changes in interest rates relating to its revolving credit facility and other debt obligations. The revolving credit facility bears interest at a variable rate based on the U.S. prime rate or LIBOR. The Company’s outstanding borrowings on the credit facility, including bank overdrafts, were approximately $19.5 million as of July 1, 2006. The remainder of the Company’s interest bearing debt obligations, including capital lease obligations, is denominated in Singapore dollars and British pounds and bears interest at a fixed rate. As of July 1, 2006, the face amounts of the outstanding borrowings on these fixed rate debt obligations were approximately $7.2 million. If interest rates were to change by a full percentage point, the net impact on interest expense would be approximately $0.2 million per year.

Foreign Currency Risk The Company faces foreign currency risks primarily as a result of its acquired Singapore and United Kingdom operations and the intercompany balances between its U.S. and these international operations which are denominated in U.S. dollars. The functional currency of the Company’s Singapore operations is the Singapore dollar. The Company has debt and other long-term obligations of approximately $7.8 million that are denominated in Singapore dollars and mature over the next four years. If the U.S. dollar weakens relative to the Singapore dollar, additional funds may be required to meet these obligations if the debt cannot be adequately serviced from the Singapore operations. Fluctuations in exchange rates between the U.S. dollar and the Singapore dollar could lead to additional currency exchange losses or gains on the intercompany balances and transactions denominated in currencies other than the functional currency. For the second quarter of fiscal 2006, the Company recorded no foreign currency transaction gains or losses on the intercompany balances between the U.S. and Singapore operations; and recorded approximately $0.3 million of foreign currency transaction gains on sales with external parties. From the date of the ClearLab International acquisition, July 24, 2002, through August 3, 2006 the exchange rate has fluctuated approximately 10.5 percent (weakening of the U.S. dollar). If the Singapore dollar were to weaken against the U.S. dollar by 10 percent, the Company would record a $2.6 million dollar foreign currency loss on the intercompany balances that exist as of July 1, 2006.

The functional currency of the Company’s United Kingdom operations is the British pound. Fluctuations in exchange rates between the U.S. dollar and the British pound could lead to additional currency exchange losses or gains on intercompany balances and transactions denominated in currencies other than the functional currency. For the second quarter of fiscal 2006, the Company recorded foreign currency transaction gains of approximately $0.5 million on the intercompany balances between the U.S. and United Kingdom operations. From the date of the ClearLab UK acquisition, February 24, 2004, through August 3, 2006 the exchange rate has fluctuated approximately 0.5 percent (weakening of the U.S. dollar). If the British pound were to weaken against the U.S. dollar by 10 percent, the Company would record a $1.6 million dollar foreign currency loss on the intercompany balances that exist as of July 1, 2006.

The Company has not entered into any foreign currency derivative financial instruments; however, it may choose to do so in the future in an effort to manage or hedge its foreign currency risk.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures. The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the Company’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report (the “Evaluation Date”), have concluded that, as of the Evaluation Date, the Company’s disclosure controls and procedures were adequate and effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities.

(b) Changes in internal controls over financial reporting. There were no significant changes in the Company’s internal controls over financial reporting or in other factors that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting subsequent to the Evaluation Date. As a result, no corrective actions were taken.

The Company’s management, including its Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s disclosure controls and procedures or its internal controls over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time the Company is involved in legal matters generally incidental to its business. It is the opinion of management, after discussion with legal counsel that, except for legal and professional fees that the Company incurs from time to time, the ultimate dispositions of all of these matters will not have a material impact on the financial position, liquidity or results of operations of the Company. However, there can be no assurance that the Company will be successful in its efforts to satisfactorily resolve these matters, and the ultimate outcome could result in a material negative impact on the Company’s financial position, liquidity or results of operations.

Item 1A. Risk Factors

Other than the additional risk factors set forth below, there are no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2005.

The Company has expended significant resources in the development of its ClearLab operations and may not realize value equal to its investment.

On July 26, 2006, the Company announced that it had engaged an investment bank to assist in performing a strategic review of its ClearLab operations. The Company is in the preliminary stages of this review and does not know what conclusions may be reached or what its ultimate actions related to ClearLab will be. The Company has invested significant amounts in acquiring and developing ClearLab and its operations and products and may not realize value equal to its investment.

The Company’s strategic review of ClearLab may result in the Company continuing to own a portion or all of ClearLab and may require that the Company expend significant additional amounts to develop its ClearLab operations.

Based on its strategic review of ClearLab, the Company may determine to retain a portion or all of ClearLab and may continue developing its operations and products. In order to fully commercialize its products, particularly the AquaSoft Singles product, the Company anticipates that ClearLab will require significant additional funding over the foreseeable future.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission of Matters to a Vote of Security Holders

The annual meeting of stockholders of the Company was held on May 19, 2006. The stockholders approved the following matters:

· The election as directors of E. Dean Butler and Stephen L. Key to serve until the annual meeting of stockholders in 2009 and until their respective successors are elected and qualified.

	Votes Cast
	For	Withheld
E. Dean Butler	11,211,190	580,599
Stephen L. Key	11,446,455	345,334

As of the date of the annual meeting of stockholders, the other directors of the Company included the following persons: (i) Jonathan C. Coon and Bradley T. Knight, who are serving until the annual meeting of stockholders in 2007; and Thomas H. Boggs, Jr., John F. Nichols and Garth T. Vincent who are serving until the annual meeting of stockholders in 2008.

· Ratification of appointment of KPMG LLP as independent auditors to audit the Company’s books and accounts for the fiscal year ending December 30, 2006.

Votes Cast:
For		11,790,713
Against or Withheld		976
Abstentions and Broker Non-Votes		100

Item 5. Other Information

None.

Item 6. Exhibits

(A) Exhibits

Exhibit No.		Description of Exhibit
3.1 (i)		Restated Certificate of Incorporation of the Company. (1)
3.1 (ii)		Restated By-Laws of the Company. (1)
4.1		Form of certificate representing shares of Common Stock, $0.1 par value per share. (2)
31.1		Certification Required Pursuant to Section 302 of the Sarbanes-Oxley Act of2002.
31.2		Certification Required Pursuant to Section 302 of the Sarbanes-Oxley Actof 2002.
32.1		Certification Required Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2		Certification Required Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(1) Incorporated by reference to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended April 4, 1998 (Commission File No. 0-23633).

(2) Incorporated by reference to the same numbered exhibit to the Company’s Registration Statement on Form S-1 (Registration No. 333-41055).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	1-800 CONTACTS, INC.


Dated: August 10, 2006	By:	/s/ Jonathan C. Coon
			Name: Jonathan C. Coon
			Title: Chief Executive Officer

	By:	/s/ Robert G. Hunter
	Name: Robert G. Hunter
	Title: Chief Financial Officer